Clarke B, Till J, Rowland E, Ward D E, Barnes P J, Shinebourne E A
Lancet. 1987 Feb 7;1(8528):299-301. doi: 10.1016/s0140-6736(87)92027-7.
Adenosine (0.05-0.25 mg/kg intravenously) successfully terminated resistant supraventricular tachycardia (SVT) in three seriously ill newborn infants and one older child. Termination of tachycardia was achieved in each case within 20 s. Adenosine, unlike many other anti-arrhythmic agents, has no substantial negative inotropic effect under these circumstances and may become the drug of choice in haemodynamically compromised children with SVT. However, it has no value in prophylaxis against recurrent SVT.
静脉注射腺苷(0.05 - 0.25毫克/千克)成功终止了3例重症新生儿和1例大龄儿童的顽固性室上性心动过速(SVT)。在每例患儿中,心动过速均在20秒内终止。与许多其他抗心律失常药物不同,在这种情况下腺苷没有明显的负性肌力作用,可能会成为血流动力学不稳定的室上性心动过速患儿的首选药物。然而,它对预防室上性心动过速复发没有作用。